REMARKS

The specification and the Abstract have been amended to correct an inadvertent error in formulae (1-1) and (1-2) for Z, wherein X in the formulae has been changed to X. The basis for the change can be seen in the subsequent disclosure of X at, e.g., page 7, line 1, and the overall disclosure at, e.g., page 6, line 18 to page 7, line 9 in the application.

New claims 45-54 merely convert original claims 33 and 35-43 to method claims.

New claims 45-54 correspond to the Group VII claims in the Restriction Requirement issued October 4, 2001 in parent application 09/830,167.

Entry of the above amendment is respectfully requested.

Respectfully submitted,

Susan & Mack

Susan J. Mack

Registration No. 30,951

SUGHRUE MION, PLLC 2100 Pennsylvania Avenue, N.W. Washington, D.C. 20037-3213 Telephone: (202) 293-7060 Facsimile: (202) 293-7860

Date: January 4, 2002

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Amend the specification by inserting before the first line of the sentence:

This is a Divisional of Application No. 09/830,167 filed April 23, 2001, the disclosure

of which is incorporated herein by reference.

Page 6, the paragraph at lines 18-19 with formulas (1-1) to (1-5):

IN THE CLAIMS:

Claims 1-44 are canceled.

Claims 45-54 are added.

IN THE ABSTRACT OF DISCLOSURE:

The abstract is changed as follows:

Compounds expressed by the following general formula (1),

$$R_{02}O^{(1)}$$
 OR_{01}
 OR_{01}

[wherein, R_{01} and R_{02} are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)].

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.